Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Autonomic nervous system imbalance, Dizziness, Hypersensitivity, Mast cell activation syndrome, Postural orthostatic tachycardia syndrome
Clinical narrative: This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 36 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administration date 24Apr2021 11:30 (Lot number: EWO171) at the age of 36 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Colitis ulcerative" (unspecified if ongoing); "Penicillin" (unspecified if ongoing). Concomitant medication(s) included: PROBIOTIC; FISH OIL; TURMERIC; MAGNESIUM. Other medications the patient received within 2 weeks of vaccination: multivitamin. Past drug history included: Keflex, reaction(s): "Allergy_keflex"; Azithromycin, reaction(s): "Allergy_Azithromycin"; Asacol, reaction(s): "Allergy_Asacol"; Remicade, reaction(s): "Allergy_Remicade". Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EWO150, Location of injection: Arm Left), administration date: 03Apr2021, when the patient was 36 years old, for Covid-19 immunization, reaction(s): "muscle twitching", "Worsening of my long Covid peripheral neuropathy symptoms (paresthesias)", "Worsening of my long Covid peripheral neuropathy symptoms (paresthesias)", "I have also developed new allergic-like reactions to many things (foods, environmental triggers, but no IgE allergies)"; Flu vaccine, for immunization, reaction(s): "Allergy_flu vaccine". The following information was reported: MAST CELL ACTIVATION SYNDROME (disability, medically significant) with onset 26Apr2021 06:00, outcome "not recovered", described as "mast cell activation syndrome"; RASH (disability) with onset 26Apr2021 06:00, outcome "not recovered", described as "rash"; URTICARIA (disability) with onset 26Apr2021 06:00, outcome "not recovered", described as "hives"; TACHYCARDIA (disability) with onset 26Apr2021 06:00, outcome "not recovered", described as "tachycardia"; DIZZINESS (disability) with onset 26Apr2021 06:00, outcome "not recovered", described as "extreme dizziness"; HYPERSENSITIVITY (disability) with onset Apr2021, outcome "not recovered", described as "presumed allergic reaction/I have also developed new allergic-like reactions to many things (foods, environmental triggers, but no IgE allergies)"; AUTONOMIC NERVOUS SYSTEM IMBALANCE (disability) with onset 26Apr2021 06:00, outcome "not recovered", described as "POTS-like dysautonomia"; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (disability) with onset 26Apr2021 06:00, outcome "not recovered", described as "orthostatic tachycardia". The patient had new onset POTS-like dysautonomia that began with extreme swings between overactive parasympathetic and sympathetic nervous system, then regularized into orthostatic tachycardia. The patient was still suffering from orthostatic tachycardia 7 months out. The patient also developed new allergic-like reactions to many things (foods, environmental triggers, but no IgE allergies) starting with vaccine reaction in Apr. A specialist thought the patient may have mast cell activation syndrome. The events "mast cell activation syndrome", "presumed allergic reaction/i have also developed new allergic-like reactions to many things (foods, environmental triggers, but no ige allergies)", "pots-like dysautonomia", "orthostatic tachycardia" were evaluated at the physician office visit. The events "rash", "hives", "tachycardia" and "extreme dizziness" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (May2021) negative; (Oct2021) negative; (Nov2021) negative; (Dec2021) negative. Therapeutic measures were taken as a result of mast cell activation syndrome, rash, urticaria, tachycardia, dizziness, hypersensitivity, autonomic nervous system imbalance, postural orthostatic tachycardia syndrome. The patient was given prednisone for presumed allergic reaction. Other treatment received for the adverse event included Salt supplements, electrolytes, physical therapy.  No follow-up attempts are possible. No further information is expected.